3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Breast Neoplasms
193
Carcinoma, Non-Small-Cell Lung
160
Ovarian Neoplasms
96
Lung Neoplasms
58
Fallopian Tube Neoplasms
57
Neoplasms
50
Triple Negative Breast Neoplasms
36
Neoplasm Metastasis
36
Esophageal Neoplasms
22
Carcinoma, Ovarian Epithelial
22
Parkinson Disease 4, Autosomal Dominant Lewy Body
21
Stomach Neoplasms
20
Squamous Cell Carcinoma of Head and Neck
20
Head and Neck Neoplasms
19
Endometrial Neoplasms
19
Adenocarcinoma of Lung
17
Melanoma
15
Breast Neoplasms, Male
15
Urinary Bladder Neoplasms
13
Carcinoma
12
Uterine Cervical Neoplasms
11
Recurrence
11
Carcinoma, Squamous Cell
11
Brenner Tumor
11
Adenocarcinoma Of Esophagus
10
Small Cell Lung Carcinoma
9
Peritoneal Neoplasms
9
Esophageal Squamous Cell Carcinoma
9
Adenocarcinoma, Bronchiolo-Alveolar
9
Prostatic Neoplasms
8
Interventions
tucatinib
1
pralsetinib
1
pertuzumab
1
ipatasertib
1
inavolisib
1
entrectinib
1
atezolizumab
1
alectinib
1
Trastuzumab
1
Tiragolumab
1
Paclitaxel
1
Ado-Trastuzumab Emtansine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Advanced Unresectable or Metastatic Solid Malignancy
×
Paclitaxel
×
Clear all
NCT04632992
2025-01-08
MyTACTIC
Genentech, Inc.
Phase 2
Completed
252 enrolled
27 charts